-
Wednesday, March 11th, 2015
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine -
Thursday, March 5th, 2015
Soligenix to Present at the 27th Annual ROTH Conference -
Tuesday, March 3rd, 2015
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients -
Friday, February 13th, 2015
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC -
Wednesday, February 11th, 2015
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC -
Saturday, February 7th, 2015
FDA Grants Soligenix “Fast Track” Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma -
Thursday, February 5th, 2015
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City -
Monday, February 2nd, 2015
Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC -
Thursday, January 29th, 2015
Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine -
Monday, January 5th, 2015
Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome -
Monday, December 29th, 2014
Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data -
Wednesday, December 24th, 2014
Soligenix Announces Closing of Public Offering of Units -
Friday, December 19th, 2014
Soligenix Announces Pricing of Public Offering of Units -
Thursday, December 11th, 2014
Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program -
Wednesday, December 10th, 2014
Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer -
Monday, November 17th, 2014
Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board -
Monday, November 10th, 2014
Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma -
Tuesday, September 23rd, 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development -
Friday, September 19th, 2014
Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine -
Wednesday, September 17th, 2014
Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
